Legal Representation
Attorney
Lawrence M. Green
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 14, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Feb 14, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Feb 14, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Aug 2, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 2, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 2, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 1, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 22, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Research and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
ASTROCYTES TO NEURONS
Pseudo Mark
AMYLOID TAU NEURODEGENERATION
Classification
International Classes
005